- Home
- AEC vs TCRX Comparison
AEC vs TCRX Comparison
Compare AEC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEC | TCRX |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | Canada | United States |
| Employees | 15 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.9M | 75.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEC | TCRX |
|---|---|---|
| Price | $4.95 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 44.7K | ★ 416.6K |
| Earning Date | 05-01-2015 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.66 | $0.85 |
| 52 Week High | $12.49 | $2.57 |
Technical Indicators
Market Signals| Indicator | AEC | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 41.90 |
| Support Level | $4.94 | $0.91 |
| Resistance Level | $5.27 | $1.16 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 95.97 | 31.00 |
Price Performance
Historical ComparisonAbout AEC Anfield Energy Inc.
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.